In this New Year episode of the Making Medicine Podcast, we revisit a full-length conversation with U.S. Senator Thom Tillis of North Carolina, focused on the policies shaping US life sciences. The discussion explores intellectual property, drug pricing dynamics, regulatory balance, and how innovation ecosystems grow at the state and national level. The episode examines approaches to sustaining research and development while maintaining global competitiveness. It also considers the long-term implications of regulatory uncertainty and international competition.
Which policy issue do you think most impacts biotech innovation today?
How should decision-makers balance affordability and long-term R&D investment?
What does the US need to maintain leadership in life sciences?
If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more: https://x.com/MakingMedPod https://www.instagram.com/makingmedicinepod/ https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=true
Timestamps:
0:00 Episode disclaimer
0:17 Welcome to Making Medicine and episode overview
0:30 Why this conversation matters for 2026
1:24 Introducing Senator Thom Tillis
2:16 Building a life sciences ecosystem in North Carolina
3:43 Economic impact of biotech investment
4:27 Tax and regulatory strategy for innovation
7:52 Balancing reform and economic stability
9:58 Why intellectual property matters for life sciences
12:18 Government involvement and innovation risks
13:51 Drug pricing policy and unintended consequences
17:05 R&D investment impacts and innovation trade-offs
20:26 Global competition and China’s growing role
22:55 Changing the narrative around life sciences
26:52 What’s next after public service
28:58 Closing reflections and future outlook
DISCLAIMER: We’re reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor.
